If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 8.59% on an annualized basis producing an average annual return of 19.49%. Currently, Boston Scientific has a market
$100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 20 years by 21.89% on an annualized basis producing an average annual return of 30.21%. Currently, Intuitive Surgical has a m
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Truist Secu
Arrowhead Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 139.33% HC Wainwright & Co. $90 → $60 Maintains Buy 06/26/2024 139.33% Chardan Capital $60 → $6
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $
How Is The Market Feeling About Intuitive Surgical?
Intuitive Surgical's (NYSE:ISRG) short percent of float has risen 4.59% since its last report. The company recently reported that it has 4.03 million shares sold short, which is 1.14% of all regular s
Peering Into Boston Scientific's Recent Short Interest
Boston Scientific's (NYSE:BSX) short percent of float has fallen 13.19% since its last report. The company recently reported that it has 11.54 million shares sold short, which is 0.79% of all regular
What 14 Analyst Ratings Have To Say About Stryker
Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings, offeri
Stryker Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 8.47% Evercore ISI Group $370 → $365 Maintains Outperform 05/30/2024 10.55% Goldman Sachs → $37
Intuitive Surgical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 -3% Evercore ISI Group $385 → $425 Maintains In-Line 05/30/2024 14.12% Goldman Sachs → $500 Ini
Boston Scientific Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 6.2% Evercore ISI Group $78 → $81 Maintains Outperform 06/18/2024 7.51% Needham $82 → $82 Reite
STAAR Surgical Ticks Higher Amid Takeover Speculation
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.43% on an annualized basis producing an average annual return of 19.36%. Currently, Vertex Pharmaceuticals
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Raymond James Initiates Coverage On Axogen With Outperform Rating, Announces Price Target of $13
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price Target of $13.
Axogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 78.33% Raymond James → $13 Initiates Coverage On → Outperform 06/20/2024 105.76% Canaccord Genu
Trump Media & Technology And Grindr Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 23 - June 29): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Tempus AI, Inc. (NASDAQ:TEM) shares jumped 30.43% after the company announced it received U.S. FDA 510(k) cle
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Guardant Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 18.07% Guggenheim → $36 Upgrades Neutral → Buy 06/04/2024 24.63% Canaccord Genuity $30 → $38 Ma
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds